{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T16:52:28Z","timestamp":1789404748521,"version":"build-2803163510"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T00:00:00Z","timestamp":1701907200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.thromres.2023.11.021","type":"journal-article","created":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T11:02:41Z","timestamp":1701514961000},"page":"153-164","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Venous thromboembolism prophylaxis and multiple myeloma patients in real-life: Results of a large survey and clinical guidance recommendations from the IFM group"],"prefix":"10.1016","volume":"233","author":[{"given":"Laurent","family":"Frenzel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Decaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Macro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Belhadj-Merzoug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salomon","family":"Manier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Touzeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Leleu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Fr\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lecompte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Perrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Avet-Loiseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Chalayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.thromres.2023.11.021_bb0005","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1182\/blood-2008-04-151076","article-title":"Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma","volume":"112","author":"Kristinsson","year":"2008","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.thromres.2023.11.021_bb0010","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1182\/blood-2009-11-252072","article-title":"Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study","volume":"115","author":"Kristinsson","year":"2010","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.thromres.2023.11.021_bb0015","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ctrv.2008.02.003","article-title":"A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma","volume":"34","author":"Hicks","year":"2008","journal-title":"Cancer Treat. Rev."},{"issue":"2","key":"10.1016\/j.thromres.2023.11.021_bb0020","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.thromres.2023.11.021_bb0025","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/bjh.18432","article-title":"Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: analysis of vascular thrombotic events in the GRIFFIN study","volume":"199","author":"Sborov","year":"2022","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.thromres.2023.11.021_bb0030","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/bjh.18452","article-title":"Vascular thrombotic events in the era of modern myeloma therapy","volume":"199","author":"Mai","year":"2022","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.thromres.2023.11.021_bb0035","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1186\/1471-2407-14-915","article-title":"Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring","volume":"14","author":"Chari","year":"2014","journal-title":"BMC Cancer"},{"issue":"13","key":"10.1016\/j.thromres.2023.11.021_bb0040","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1182\/blood-2005-07-2817","article-title":"Combination therapy with lenalidomide plus dexamethasone (Rev\/Dex) for newly diagnosed myeloma","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.thromres.2023.11.021_bb0045","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1002\/cncr.28274","article-title":"Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma","volume":"119","author":"Fouquet","year":"2013","journal-title":"Cancer"},{"issue":"21","key":"10.1016\/j.thromres.2023.11.021_bb0050","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 1","key":"10.1016\/j.thromres.2023.11.021_bb0055","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/j.thromres.2012.08.279","article-title":"Thrombosis in myeloma treated with IMiDs","volume":"130","author":"Leleu","year":"2012","journal-title":"Thromb. Res."},{"issue":"26","key":"10.1016\/j.thromres.2023.11.021_bb0060","doi-asserted-by":"crossref","first-page":"5838","DOI":"10.1182\/blood-2010-08-303487","article-title":"Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)","volume":"116","author":"Zonder","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.thromres.2023.11.021_bb0065","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.thromres.2023.11.021_bb0070","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/2042098612452291","article-title":"Venous and arterial thrombotic risks with thalidomide: evidence and practical guidance","volume":"3","author":"Palumbo","year":"2012","journal-title":"Ther. Adv. Drug Saf."},{"issue":"4","key":"10.1016\/j.thromres.2023.11.021_bb0075","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1182\/blood-2008-12-196238","article-title":"Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma","volume":"114","author":"Richardson","year":"2009","journal-title":"Blood"},{"issue":"9513","key":"10.1016\/j.thromres.2023.11.021_bb0080","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","article-title":"Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial","volume":"367","author":"Palumbo","year":"2006","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.thromres.2023.11.021_bb0085","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1365-2141.2008.07321.x","article-title":"Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma","volume":"143","author":"Lonial","year":"2008","journal-title":"Br. J. Haematol."},{"issue":"9","key":"10.1016\/j.thromres.2023.11.021_bb0090","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1080\/10428194.2021.1910687","article-title":"Venous thromboembolism in patients with multiple myeloma receiving daratumumab-based regimens: a post hoc analysis of phase 3 clinical trials","volume":"62","author":"Wang","year":"2021","journal-title":"Leuk. Lymphoma"},{"issue":"9","key":"10.1016\/j.thromres.2023.11.021_bb0095","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1002\/cam4.2945","article-title":"Once-weekly (70 mg\/m2) vs twice-weekly (56 mg\/m2) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: a post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION-1 trials","volume":"9","author":"Moreau","year":"2020","journal-title":"Cancer Med."},{"issue":"1","key":"10.1016\/j.thromres.2023.11.021_bb0100","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/bjh.17772","article-title":"Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis","volume":"196","author":"Piedra","year":"2022","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.thromres.2023.11.021_bb0105","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/ajh.26806","article-title":"Thrombosis in multiple myeloma: risk estimation by induction regimen and association with overall survival","volume":"98","author":"Charalampous","year":"2023","journal-title":"Am. J. Hematol."},{"issue":"10","key":"10.1016\/j.thromres.2023.11.021_bb0110","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.thromres.2023.11.021_bb0115","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12634","article-title":"Evaluation of the Khorana score for prediction of venous thromboembolism in patients with multiple myeloma","volume":"6","author":"Sanfilippo","year":"2022","journal-title":"Res. Pract. Thromb. Haemost."},{"issue":"6","key":"10.1016\/j.thromres.2023.11.021_bb0120","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2013.48.7934","article-title":"International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation","volume":"32","author":"Palumbo","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.thromres.2023.11.021_bb0125","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.18630","article-title":"External validation of the SAVED score for venous thromboembolism risk stratification in patients with multiple myeloma receiving immunomodulatory drugs","author":"Dima","year":"2023","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.thromres.2023.11.021_bb0130","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/ajh.25603","article-title":"Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score","volume":"94","author":"Sanfilippo","year":"2019","journal-title":"Am. J. Hematol."},{"issue":"23","key":"10.1016\/j.thromres.2023.11.021_bb0135","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1182\/blood.2022015727","article-title":"Abnormal metaphase cytogenetics predicts venous thromboembolism in myeloma: derivation and validation of the PRISM score","volume":"140","author":"Chakraborty","year":"2022","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.thromres.2023.11.021_bb0140","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1111\/jth.15758","article-title":"Prediction of venous thromboembolism in patients with multiple myeloma treated with lenalidomide, bortezomib, dexamethasone, and transplantation: lessons from the substudy of IFM\/DFCI 2009 cohort","volume":"20","author":"Chalayer","year":"2022","journal-title":"J. Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.thromres.2023.11.021_bb0145","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12882-022-03041-w","article-title":"UK prescribing practice of anticoagulants in patients with chronic kidney disease: a nephrology and haematology-based survey","volume":"24","author":"Parker","year":"2023","journal-title":"BMC Nephrol."},{"issue":"1","key":"10.1016\/j.thromres.2023.11.021_bb0150","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/00185787221115311","article-title":"A description of apixaban dosing patterns for treatment or prevention of thrombotic events in hospitalized patients on dialysis","volume":"58","author":"White","year":"2023","journal-title":"Hosp. Pharm."},{"issue":"3","key":"10.1016\/j.thromres.2023.11.021_bb0155","doi-asserted-by":"crossref","first-page":"86","DOI":"10.4140\/TCP.n.2023.86","article-title":"A review of the safety and efficacy of apixaban in patients with severe renal impairment","volume":"38","author":"Ifeanyi","year":"2023","journal-title":"Sr Care Pharm."},{"issue":"1","key":"10.1016\/j.thromres.2023.11.021_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2022.100024","article-title":"Bleeding risk in patients with multiple myeloma treated for venous thromboembolism: a MarketScan analysis","volume":"7","author":"Adrianzen-Herrera","year":"2022","journal-title":"Res. Pract. Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.thromres.2023.11.021_bb0165","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s13063-023-07236-w","volume":"24","author":"Zhou","year":"2023","journal-title":"Trials"},{"issue":"9","key":"10.1016\/j.thromres.2023.11.021_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2022.101269","article-title":"Single versus dual antiplatelet therapy following left atrial appendage occlusion in patients with high bleeding risk","volume":"47","author":"Mhanna","year":"2022","journal-title":"Curr. Probl. Cardiol."},{"issue":"813","key":"10.1016\/j.thromres.2023.11.021_bb0175","first-page":"281","article-title":"Quel anticoagulant ou antiagr\u00e9gant chez le patient oncologique pr\u00e9sentant une thrombocytop\u00e9nie\u202f? [Which anticoagulant or antiplatelet treatment for cancer patients with thrombocytopenia\u202f?]","volume":"19","author":"Paoletti","year":"2023","journal-title":"Rev. Med. Suisse"},{"issue":"Suppl. 1","key":"10.1016\/j.thromres.2023.11.021_bb0180","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1016\/S0049-3848(20)30400-X","article-title":"Anticoagulant and antiplatelet treatment in cancer patients with thrombocytopenia","volume":"191","author":"Leader","year":"2020","journal-title":"Thromb. Res."},{"issue":"9","key":"10.1016\/j.thromres.2023.11.021_bb0185","article-title":"Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents","volume":"9","author":"Kahale","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"issue":"4","key":"10.1016\/j.thromres.2023.11.021_bb0190","first-page":"844","article-title":"MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs","volume":"110","author":"Leleu","year":"2013","journal-title":"Thromb. Haemost."},{"issue":"8","key":"10.1016\/j.thromres.2023.11.021_bb0195","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1200\/JCO.2010.31.6844","article-title":"Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial","volume":"29","author":"Palumbo","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.thromres.2023.11.021_bb0200","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/blood-2011-03-344333","article-title":"Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide","volume":"119","author":"Larocca","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2023.11.021_bb0205","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.thromres.2022.03.001","article-title":"Safety and efficacy of apixaban as thromboprophylaxis in myeloma patients receiving chemotherapy: a prospective cohort study","volume":"213","author":"Sayar","year":"2022","journal-title":"Thromb. Res."},{"issue":"13","key":"10.1016\/j.thromres.2023.11.021_bb0210","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","article-title":"Rivaroxaban or aspirin for extended treatment of venous thromboembolism","volume":"376","author":"Weitz","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.thromres.2023.11.021_bb0215","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3892\/ol.2022.13235","article-title":"Prophylaxis of cancer-associated venous thromboembolism with low-molecular-weight heparin-tinzaparin: real world evidence","volume":"23","author":"Christopoulou","year":"2022","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.thromres.2023.11.021_bb0220","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.thromres.2021.08.027","article-title":"Extended thromboprophylaxis post gynaecological cancer surgery; the effect of weight adjusted and fixed dose LMWH (Tinzaparin)","volume":"207","author":"Abu Saadeh","year":"2021","journal-title":"Thromb. Res."},{"issue":"24","key":"10.1016\/j.thromres.2023.11.021_bb0225","doi-asserted-by":"crossref","first-page":"6216","DOI":"10.3390\/cancers14246216","article-title":"Approach to contemporary risk assessment, prevention and management of thrombotic complications in multiple myeloma","volume":"14","author":"Fotiou","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"17","key":"10.1016\/j.thromres.2023.11.021_bb0230","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.thromres.2023.11.021_bb0235","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.thromres.2023.11.021_bb0240","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.thromres.2023.11.021_bb0245","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/bjh.15392","article-title":"Safety and efficacy of apixaban for routine thromboprophylaxis in myeloma patients treated with thalidomide- and lenalidomide-containing regimens","volume":"185","author":"Storrar","year":"2019","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.thromres.2023.11.021_bb0250","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/ajh.25459","article-title":"Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study","volume":"94","author":"Pegourie","year":"2019","journal-title":"Am. J. Hematol."},{"issue":"4","key":"10.1016\/j.thromres.2023.11.021_bb0255","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/bjh.16653","article-title":"Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents","volume":"190","author":"Cornell","year":"2020","journal-title":"Br. J. Haematol."},{"issue":"14","key":"10.1016\/j.thromres.2023.11.021_bb0260","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.thromres.2023.11.021_bb0265","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/bjh.16059","article-title":"IFM2014-04 investigators. Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014-04 (Etoile du Nord) trial","volume":"187","author":"Boyle","year":"2019","journal-title":"Br. J. Haematol."},{"issue":"7","key":"10.1016\/j.thromres.2023.11.021_bb0270","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2105872","article-title":"Abelacimab for prevention of venous thromboembolism","volume":"385","author":"Verhamme","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.thromres.2023.11.021_bb0275","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"Key","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.thromres.2023.11.021_bb0280","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.3324\/haematol.2022.280893","article-title":"Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an ad hoc expert panel","volume":"107","author":"De Stefano","year":"2022","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.thromres.2023.11.021_bb0285","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1182\/blood.2020005125","article-title":"Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials","volume":"136","author":"Bradbury","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2023.11.021_bb0290","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(09)70232-3","article-title":"Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study","volume":"10","author":"Agnelli","year":"2009","journal-title":"Lancet Oncol."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384823003377?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384823003377?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:53:08Z","timestamp":1758736388000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384823003377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":58,"alternative-id":["S0049384823003377"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2023.11.021","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Venous thromboembolism prophylaxis and multiple myeloma patients in real-life: Results of a large survey and clinical guidance recommendations from the IFM group","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2023.11.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}